Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus SALPIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus SALPIX.
CIS-MDP vs SALPIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
SALPIX (sodium chloride 0.9%, benzyl alcohol 0.9%) is a sterile, nonpyrogenic isotonic solution. It does not have a direct pharmacological mechanism of action; it is used as a vehicle or diluent for other medications and for irrigation. The benzyl alcohol component acts as a bacteriostatic preservative.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
SALPIX (hysterosalpingography contrast medium) is administered intrauterine as a single dose of 10-20 mL, instilled slowly under fluoroscopic guidance. No systemic dosing; procedure is diagnostic.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life: 1.5–2.0 hours. Short half-life necessitates frequent dosing in clinical use.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Primarily renal excretion as unchanged drug: >90% within 24 hours. Minor biliary/fecal elimination (<10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical